oraCMU® and oraCMS1® are OraPharm’s patented probiotics.
Both probiotic strains that promote oral health were isolated from
the saliva of
460 South Korean kids, who had healthy mouth.
Strain Names: Weissella cibaria CMU, CMS1
Probiotics found
in the healthy mouths
of 460 South Korean kids
between 4 and 7
Probiotics
approved
by MFDS
for use as food
ingredients
A combination of
6 mechanisms of action
which maximizes
synergistic
effects in oral cavity
2 ROK patents
& 1 U.S. patent
According to the results of the clinical trial, which compared probiotics’ adhesive properties, active oraCMU® was still observed on the surface of oral cavity of 84% of participants, who stopped taking oraCMU® 4 weeks ago.
OraCMU® was proved to be the most effective in suppressing VSC and bad breath compared With 4 other probiotic strains.
A comparative study of coaggregation of probiotics with bacteria, which cause oral diseases, found that oraCMU® more effectively disrupts bacterial activities leading to halitosis and periodontitis and prevents oral diseases than all other probiotic strains concerned.
A comparative study of antibacterial activities of probiotics found that oraCMU® is more effective to inhibit growth in bacteria which cause halitosis and periodontitis than all other probiotic strains concerned.
A comparative study of PAV of probiotic strains in carbohydrates found that oraCMU® is the least likely to influence the development of dental caries.
The clinical trial to investigate the efficacy of probiotic strains in preventing dental caries discovered that OraCMU® has greater inhibitory effects on plaque formation than probiotic strains provided by other companies.
A comparative study of probiotic strains’ inhibitory effects on plaque formation by bacteria(S. mutans) that cause dental caries discovered that oraCMU® inhibits plaque formation most efficiently.
The Probiotics, which promote oral health and were patented by OraPharm, detect certain parts of pathogenic bacteria. The probiotics and pathogenic bacteria, therefore, can be easily combined. Coaggregation of the probiotics with pathogenic bacteria enables the probiotics to block the adherence of pathogenic bacteria to epithelial cells and teeth and contribute to the elimination of pathogenic bacteria.
Bacteria that cause dental caries metabolize sugars to produce sticky substances, which contribute to plaque formation. OraPharm’s patented probiotics inhibit such bacterial activities in the oral cavity, thereby blocking biofilm(tartar or dental plaque) formation.
OraPharm’s patented probiotics secrete antimicrobial substances such as organic acids, hydronic peroxide, fatty acids, and bacteriocin outside of cells, thereby inhibiting the growth of bacteria which cause halitosis and periodontitis.
OraPharm’s patented probiotics block the adherence of pathogens, which cause halitosis or periodontitis, to epithelial cells, thereby preventing various oral diseases.
OraPharm’s patented probiotics inhibit mgl gene expression in P. gingivalis, the bacteria which produce VSC, the main cause of bad breath. The probiotics also inhibit and block METase activities.
oraCMU® inhibits the production of substances(NO, IL1β, and IL6, all of which promote inflammation) induced by general probiotics for oral health.